Microplate alamar blue assay (MABA) and Low oxygen recovery assay (LORA) for Mycobacterium tuberculosis

Methods in Molecular Biology

Volumn 1285, Issue , 2015, Pages 281-292

  Cho, Sanghyun ^a   Lee, Hyung Sup ^a   Franzblau, Scott ^a  

^a NONE

Author keywords

Aerobic; Antimicrobial activity; Growth; Hypoxia; Luminescent reporter; Metabolic activity; Minimum inhibitory concentration

Indexed keywords

ARTICLE; BACTERIAL GROWTH; BIOASSAY; COLONY FORMING UNIT; FLUORESCENCE; HIGH THROUGHPUT SCREENING; HYPOXIA; LOW OXYGEN RECOVERY ASSAY; LOW TEMPERATURE; LUMINESCENCE; MICROPLATE ALAMAR BLUE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RESAZURIN ASSAY; ANAEROBIC GROWTH; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; OXYGEN CONSUMPTION; PROCEDURES;

MYCOBACTERIUM TUBERCULOSIS;

COLORING AGENT; TUBERCULOSTATIC AGENT;

ANAEROBIOSIS; ANTITUBERCULAR AGENTS; COLORING AGENTS; DRUG DISCOVERY; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXYGEN CONSUMPTION;

EID: 84925240695     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2450-9_17     Document Type: Article

References (25)

1. Glaziou P, Falzon D, Floyd K, Raviglione M (2013) Global epidemiology of tuberculosis. Semin Respir Crit Care Med 34(1):3–16.
2. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, Meissner G, Mitchison DA, Sula L (1963) Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 29:565–578.
3. Canetti G (1970) Infection caused by atypical mycobacteria and antituberculous immunity. Lille Med 15(2):280–282.
4. Cho SH, Goodlett D, Franzblau S (2006) ICAT-based comparative proteomic analysis of non-replicating persistent Mycobacterium tuberculosis. Tuberculosis (Edinb) 86(6): 445–460.
5. Walters SB, Hanna BA (1996) Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterium growth indicator tube method. J Clin Microbiol 34(6):1565–1567.
6. Wanger A, Mills K (1996) Testing of Mycobacterium tuberculosis susceptibility to ethambutol, isoniazid, rifampin, and streptomycin by using Etest. J Clin Microbiol 34(7):1672–1676.
7. Nakayama GR, Caton MC, Nova MP, Parandoosh Z (1997) Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods 204(2):205–208.
8. Collins L, Franzblau SG (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41(5):1004–1009.
9. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, Gilman RH (1998) Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 36(2):362–366.
10. Yajko DM, Madej JJ, Lancaster MV, Sanders CA, Cawthon VL, Gee B, Babst A, Hadley WK (1995) Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol 33(9):2324–2327.
11. Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F (2002) Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46(8):2720–2722.
12. Zhang Y, Yew WW, Barer MR (2012) Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 56(5):2223–2230, AAC.06288-11 [pii].
13. Boshoff HI, Barry CE 3rd (2005) Tuberculosis – metabolism and respiration in the absence of growth. Nat Rev Microbiol 3(1):70–80.
14. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profi ling. Mol Microbiol 43(3):717–731.
15. Wayne LG, Hayes LG (1996) An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64(6):2062–2069.
16. Deb C, Lee CM, Dubey VS, Daniel J, Abomoelak B, Sirakova TD, Pawar S, Rogers L, Kolattukudy PE (2009) A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipidloaded, drug-tolerant, dormant pathogen. PLoS One 4(6):e6077.
17. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG (2007) Low-oxygenrecovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 51(4):1380–1385.
18. Heifets L, Simon J, Pham V (2005) Capreomycin is active against non-replicating M. tuberculosis. Ann Clin Microbiol Antimicrob 4:6. doi: 10.1186/1476-0711-4-6.
19. Xie Z, Siddiqi N, Rubin EJ (2005) Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 49(11):4778–4780.
20. Cooksey RC, Crawford JT, Jacobs WR Jr, Shinnick TM (1993) A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing fi refl y luciferase. Antimicrob Agents Chemother 37(6):1348–1352.
21. Lambrecht RS, Carriere JF, Collins MT (1988) A model for analyzing growth kinetics of a slowly growing Mycobacterium sp. Appl Environ Microbiol 54(4):910–916.
22. Shin SJ, Han JH, Manning EJ, Collins MT (2007) Rapid and reliable method for quantifi cation of Mycobacterium paratuberculosis by use of the BACTEC MGIT 960 system. J Clin Microbiol 45(6):1941–1948.
23. Youmans AS, Youmans GP (1948) The effect of “Tween 80” in vitro on the bacteriostatic activity of twenty compounds for Mycobacterium tuberculosis. J Bacteriol 56(2):245–252.
24. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo- Barturen I, Dick T, Dartois V, Lenaerts AJ (2012) Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis 92(6):453–488.
25. Wayne LG, Lin KY (1982) Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 37(3):1042–1049.